Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01025479

Enrollment

829

Registered

2009-12-03

Start date

2009-11-30

Completion date

2010-03-31

Last updated

2010-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis, Prostate Cancer

Keywords

Osteoporosis, Prostate cancer, LHRH agonist and/or anti-androgen agent, Korean prostate cancer

Brief summary

Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* pathologic confirmation of prostate cancer * patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Exclusion criteria

* patients who are hard to be analysed by limitation of chart record according to investigators'discretion * patients who already have been registered in this study

Design outcomes

Primary

Measure	Time frame
To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.	—

Secondary

Measure	Time frame
To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.	—

Countries

South Korea

Outcome results